SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Co. (NASDAQ:ICU) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 370,200 shares, a drop of 11.2% from the January 15th total of 416,700 shares. Currently, 5.4% of the shares of the company are sold short. Based on an average daily volume of 460,800 shares, the days-to-cover ratio is presently 0.8 days.

SeaStar Medical Price Performance

Shares of ICU traded up $0.07 during mid-day trading on Tuesday, reaching $1.86. The company had a trading volume of 177,272 shares, compared to its average volume of 619,444. The company’s 50-day moving average is $1.90 and its 200-day moving average is $3.39. The company has a market capitalization of $8.30 million, a P/E ratio of -0.16 and a beta of -1.02. SeaStar Medical has a twelve month low of $1.50 and a twelve month high of $42.92.

Institutional Trading of SeaStar Medical

An institutional investor recently raised its position in SeaStar Medical stock. Geode Capital Management LLC increased its stake in shares of SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,430 shares of the company’s stock after buying an additional 5,618 shares during the period. Geode Capital Management LLC owned 1.02% of SeaStar Medical worth $88,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.